研究单位：[1]Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,Hubei,China,430030[2]The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial)[3]Women Hospital, School of Medicine, Zhejiang University[4]Southwest Hospital, China[5]Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University[6]Sichuan Cancer Hospital and Research Institute[7]Qilu Hospital of Shandong University[8]Beijing Friendship Hospital[9]Tianjin Medical University[10]West China Second University Hospital[11]Xiangya Hospital of Central South University[12]Gansu Provincial Maternal and Child Health Care Hospital[13]Zhejiang Cancer Hospital[14]Shengjing Hospital
研究目的：
This study is an exploratory clinical trial to investigate the feasibility of neoadjuvant chemoimmunotherapy plus extrafascial hysterectomy and pelvic lymph node dissection in patients with stage IB2 (2018 FIGO) cervical cancer and to observe the response rate to treatment, adverse effects and complications, and to assess the survival rate of patients.
